- Evolva’s antibiotic GC-072 (EV-035 series) selected for contract negotiations for preclinical funding by US DTRA
Evolva’s antibiotic GC-072 (EV-035 series) selected for contract negotiations for preclinical funding by US DTRA
Reinach, Switzerland, 24 September 2013 – The US Defense Threat Reduction Agency (DTRA) has announced that it has selected Evolva to enter into contract negotiations regarding possible preclinical funding for Evolva’s antibiotic compound GC-072 (the lead compound in Evolva’s EV-035 series) under the Transformational Medical Technologies Initiative (TMTI). The size of the award could be up to USD 14.7 million.
GC-072 is a broad-spectrum antibiotic that has demonstrated utility in preclinical studies in vitro and in vivo against a wide range of bacterial pathogens, most notably Burkholderia pseudomallei. This bacterium causes the disease melioidosis, and is regarded as a potential biothreat agent.
The contract negotiations are expected to take several months to complete. There is no guarantee of a successful outcome. If successful, Evolva will provide an update that explains the publicly available parameters of this DTRA award in greater detail.
Evolva continues to pursue options to partner its pharmaceutical pipeline in line with its strategy of focusing on high value ingredients for health, wellness and nutrition.
– Ends –
|Neil Goldsmith, CEO||Jakob Dynnes Hansen, CFO||Paul Verbraeken, IR|
|[email protected]||[email protected]||[email protected]|
|+ 41 61 485 2005||+ 41 61 485 2034||+ 41 61 485 2035|
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
Stay informed Join our mailing list to receive Evolva’s press releases via e-mail.Join